Literature DB >> 15321736

M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart.

Clara Di Filippo1, Salvatore Cuzzocrea, Raffaele Marfella, Valentina Fabbroni, Giuseppe Scollo, Liberato Berrino, Dario Giugliano, Francesco Rossi, Michele D'Amico.   

Abstract

M40403 is a low-molecular-weight, synthetic manganese-containing biscyclohexylpyridine superoxide dismutase mimetic (SODm) that removes superoxide anions (O(2)(-)) without interfering with other reactive species known to be involved in cardiovascular alterations (e.g. nitric oxide [NO] and peroxynitrite [ONOO(-)]). As such, M40403 represents an important pharmacological tool to dissect the roles of O(2)(-) in functional and biochemical cardiovascular alterations induced by perfusion of high glucose concentrations into the heart. Perfusion of a high glucose concentration of glucose into the heart elicited important cardiovascular alterations characterized by QT interval prolongation, increase in coronary perfusion pressure (CPP), lipid peroxidation, decrease in MnSOD activity and DNA damage. All parameters of cardiovascular alteration were attenuated by M40403 (1-10 mg/l). Furthermore, perfusion of a high of glucose concentration induced a significant formation of nitrotyrosine as well as an activation of poly(adenosine diphosphate [ADP]-ribose) synthetase (PARS), as determined by immunohistochemical analysis of heart tissue. The extent of staining for nitrotyrosine and PARS was reduced by M40403. These results clearly indicate that O(2)(-) plays a critical role in the development of the functional and biochemical cardiovascular alterations induced by perfusion of a high concentration of glucose into the heart. Therefore, synthetic enzymes of SOD, such as M40403, offer a novel therapeutic approach for the management of various cardiovascular diseases where these radicals have been postulated to play a role.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15321736     DOI: 10.1016/j.ejphar.2004.06.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Mitochondrial therapeutics for cardioprotection.

Authors:  Raquel S Carreira; Pamela Lee; Roberta A Gottlieb
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Acute myocardial infarction in streptozotocin-induced hyperglycaemic rats: protection by a carbon monoxide-releasing molecule (CORM-3).

Authors:  Clara Di Filippo; Mauro Perretti; Francesco Rossi; Franca Ferraraccio; Roberto Motterlini; Michele D'Amico
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-22       Impact factor: 3.000

Review 3.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

4.  Novel biscapped and monocapped tris(dioxime) Mn(II) complexes: x-ray crystal structure of the first cationic tris(dioxime) Mn(II) complex [Mn(CDOH)3BPh]OH (CDOH2= 1,2-cyclohexanedione dioxime).

Authors:  Wen-Yuan Hsieh; Shuang Liu
Journal:  Inorg Chem       Date:  2006-06-26       Impact factor: 5.165

Review 5.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

6.  NO/peroxynitrite dynamics of high glucose-exposed HUVECs: chemiluminescent measurement and computational model.

Authors:  Sunil Potdar; Mahendra Kavdia
Journal:  Microvasc Res       Date:  2009-04-10       Impact factor: 3.514

7.  Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction.

Authors:  Rudo F Mapanga; Uthra Rajamani; Nonkululeko Dlamini; Makhosazane Zungu-Edmondson; Roisin Kelly-Laubscher; Mohammed Shafiullah; Athiq Wahab; Mohamed Y Hasan; Mohamed A Fahim; Philippe Rondeau; Emmanuel Bourdon; M Faadiel Essop
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.